The tone when conveying a diagnosis of Alzheimer’s disease is moving from a hushed whisper to a rising chorus of hope. Disease-modifying therapies and novel blood tests integrated into clinical practice are ushering in a new approach, facilitating more discussion around cognition than ever before. A wave of digital technologies and AI applied to speech, sleep, and everyday activities will provide new paths to early detection, and a pipeline of drug therapies holds promise. Innovative payment models are helping to promulgate comprehensive dementia-care programs. It’s time to demonstrate impact and effectiveness, so that the 7.2 million Americans now living with Alzheimer’s are guided not by fear, but by hope.